Metrics as of 10/17/2026, 12:47 AM (Berlin time), refresh in progress.
Dyne Therapeutics Stock
Dyne Therapeutics, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- John G. Cox
- Employees
- 289
- Market cap
- $2.7 B
- IPO
- 17/09/2020
Dyne Therapeutics, Inc. is a U.S.-based biotechnology firm operating within the Healthcare sector. The company is headquartered in Waltham and was founded in 2017. It is listed on the NASDAQ under the ticker symbol DYN. Dyne Therapeutics focuses on developing advanced treatments for genetically driven muscle…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Dyne Therapeutics stock: price history
1D
-6.8%
1W
-14.4%
1M
-17.7%
6M
-30.2%
YTD
-27.1%
1Y
-13.2%
2Y
-59.7%
5Y
-4.2%
10Y
–
Next earnings date
Next earnings date
04/11/2026 (in 18 days)
Volatility around earnings
~6% stronger price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vdouble-bottom-top-v1.0 on 13/10/26. Not a buy or sell signal.Beta
What does this mean?
Double top
BearishThe price failed at a similar high twice, with a pullback in between. This M-shaped pattern is a classic reversal signal from an uptrend into a downtrend.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
Dyne Therapeutics stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 17/10/2026.
Business model & megatrends
Robust business model that benefits noticeably from at least one megatrend.
Dyne Therapeutics is a US-based biotechnology company focused on developing advanced therapies for genetically determined muscle disorders. The company leverages its proprietary FORCE platform to develop disease-modifying therapeutics. Research activities are directed against various conditions such as Myotonic Dystrophy Type 1, Duchenne Muscular Dystrophy, Facioscapulohumeral Dystrophies, and other rare skeletal, cardiac, or metabolic muscle disorders. As the company is currently operating in the research and development phase, no current revenue segments or product sales are reported.
- Revenue model
- Transactional
- Recurring revenue
- None
- Pricing power
- Strong
- Moat
- Narrow
- Moat type
- Efficient scale
- Capital intensity
- High
- Customer concentration
- Unknown
Ask the agents about Dyne Therapeutics
Analyst assessment of Dyne Therapeutics
PRICE TARGET LOW
US$24.00
CONSENSUS
US$35.20
MEDIAN
US$34.50
PRICE TARGET HIGH
US$50.00
1
STRONG BUY
11
BUY
1
HOLD
1
SELL
0
STRONG SELL
14
TOTAL · Buy
As of: 30/09/2026
Dyne Therapeutics stock metrics
P/E
-4.28
P/B
3.36
EV/EBITDA
-4.05
RETURN ON EQUITY
-25.4%
NET MARGIN
0.0%
DEBT/EQUITY
0.03
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
82.1%
FLOAT SHARES
153,332,659
AVG. DAILY VOLUME (30D)
3,741,620
Insider transactions (SEC)
Posner Brian S
Kerr Douglas
Friedl-Naderer Johanna
Friedl-Naderer Johanna
Cox John
Institutional holders
Comparable stocks
Frequently asked questions about Dyne Therapeutics stock
What does Dyne Therapeutics do?
Dyne Therapeutics, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is John G. Cox, the company employs around 289 people.
The IPO was on 17/09/2020; the stock trades on NASDAQ under the ticker DYN.
What do analysts say about Dyne Therapeutics stock?
14 analysts rate the stock, the consensus is Buy (as of 30/09/2026).
The average price target is US$35.20, ranging from US$24.00 to US$50.00, with a median of US$34.50.
This is an external assessment, not a statement by Market Jury.
When does Dyne Therapeutics report next?
The next earnings date is 04/11/2026.
Around past earnings, price swings were roughly 6% stronger than usual.
Does Dyne Therapeutics pay a dividend?
No, Dyne Therapeutics currently does not pay a dividend.
Which stocks are comparable to Dyne Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Dyne Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Dyne Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.